CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 194 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |
| Avoro Capital Advisors LLC | 10,300,000 | $153,573,000 | 2.40% |
| Nicholas Investment Partners, LP | 1,840,014 | $27,434,609 | 2.05% |
| RA Capital Management | 6,940,000 | $103,475,400 | 2.04% |
| Perceptive Advisors | 4,043,191 | $60,283,978 | 2.01% |
| Novo Holdings A/S | 1,566,521 | $23,356,828 | 1.73% |
| Bain Capital Life Sciences Investors, LLC | 913,969 | $13,627,278 | 1.52% |
| HighVista Strategies LLC | 180,305 | $2,688,348 | 1.24% |
| Ghost Tree Capital, LLC | 237,900 | $3,547,089 | 1.17% |
| EAM Investors, LLC | 381,564 | $5,689,119 | 1.10% |
| Connacht Asset Management LP | 11,986 | $178,711 | 1.06% |
External links
This page lists CYMABAY THERAPEUTICS INC's shareholders in Q3 2023. To view CYMABAY THERAPEUTICS INC's shareholder history, click here.